Infliximab plus plasma exchange rescue therapy in Kawasaki disease

Journal of Pediatrics

Volumn 164, Issue 5, 2014, Pages

  Sonoda, Kaori ^a   Mori, Masaaki ^a   Hokosaki, Tatsunori ^a   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Bacille de Calmette et Gu rin; BCG; C reactive protein; CAL; Coronary artery lesions; CRP; FC; Fractional change; IFX; IL; Infliximab; Interleukin; Intravenous immunoglobulin; IVIG; Kawasaki disease; KD; PE; Plasma exchange; TB; TNF; Tuberculosis; Tumor necrosis factor

Indexed keywords

AMINOTRANSFERASE; ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; IMMUNOGLOBULIN; INFLIXIMAB; PREDNISOLONE;

ADVERSE OUTCOME; AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ARTICLE; BODY TEMPERATURE; CERVICAL LYMPHADENOPATHY; CHILD; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; DRUG ERUPTION; FEMALE; FEVER; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUTROPHIL COUNT; ONSET AGE; PHLEBITIS; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SYNOVITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMA EXCHANGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899048257     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2014.01.020     Document Type: Article

References (23)

1. K. Furusho, T. Kamiya, H. Nakano, N. Kiyosawa, K. Shinomiya, and T. Hayashidera et al. High-dose intravenous gammaglobulin for Kawasaki disease Lancet 2 1984 1055 1058
2. J.W. Newburger, M. Takahashi, A.S. Beiser, J.C. Burns, J. Bastian, and K.J. Chung et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome N Engl J Med 324 1991 1633 1639
3. National survey group for Kawasaki disease, the NPO Japan Research Center for Kawasaki Disease. The 21st research results of national survey of Kawasaki disease. September 2011 (in Japanese). Available at: http://www.jichi.ac.jp/dph/ kawasakibyou/20110915/mcls21report.pdf.
4. A.H. Tremoulet, B.M. Best, S. Song, S. Wang, E. Corinaldesi, and J.R. Eichenfield et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease J Pediatr 153 2008 117 121
5. J.C. Burns, W.H. Mason, S.B. Hauger, H. Janai, J.F. Bastian, and J.D. Wohrley et al. Infliximab treatment for refractory Kawasaki syndrome J Pediatr 146 2005 662 667
6. J.C. Burns, B.M. Best, A. Mejias, L. Mahony, D.E. Fixler, and H.S. Jafri et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease J Pediatr 153 2008 833 838
7. M.B. Son, K. Gauvreau, J.C. Burns, E. Corinaldesi, A.H. Tremoulet, and V.E. Watson et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study J Pediatr 158 2011 644 649
8. M. Mori, T. Imagawa, R. Hara, M. Kikuchi, T. Hara, and T. Nozawa et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series J Rheumatol 39 2012 864 867
9. M. Mori, T. Imagawa, K. Yasui, A. Kanaya, and S. Yokota Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease J Pediatr 137 2000 177 180
10. Research Committee on Kawasaki Disease Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease 1984 Japanese Ministry of Health and Welfare Tokyo, Japan
11. M. Mori, T. Imagawa, and S. Yokota Infliximab therapy for intractable Kawasaki disease Rheumatology 48 2012 683 690 (in Japanese)
12. T. Imagawa, M. Mori, T. Miyamae, S. Ito, T. Nakamura, and K. Yasui et al. Plasma exchange for refractory Kawasaki disease Eur J Pediatr 163 2004 263 264
13. M. Mori, T. Imagawa, S. Katakura, T. Miyamae, K. Okuyama, and S. Ito et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin Mod Rheumatol 14 2004 43 47
14. M. Mori Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin Nihon Rinsho 66 2008 349 354
15. T. Hokosaki, M. Mori, T. Nishizawa, T. Nakamura, T. Imagawa, and M. Iwamoto et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease Pediatr Int 54 2012 99 103
16. D.S. Kim Serum interleukin-6 in Kawasaki disease Yonsei Med J 33 1992 183 188
17. T. Matsubara, S. Furukawa, and K. Yabuta Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions Clin Immunol Immunopathol 56 1990 29 36
18. D.Y. Leung, R.S. Geha, J.W. Newburger, J.C. Burns, W. Fiers, and L.A. Lapierre et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome J Exp Med 164 1986 1958 1972
19. Research Task of the Research Council, the Japanese Society of Pediatric Cardiology and Cardiac Surgery "Guidelines for management of acute phase Kawasaki disease" (Heisei 24 revised edition) Pediatr Cardiol Cardiac Surg 28 2012 15 19 (in Japanese)
20. WHO Library Cataloguing-in-Publication Data. Global tuberculosis report 2012. Available at: www.who.int/tb/publications/global-report/gtbr12-main.pdf.
21. W.S. Kim, J.I. Choi, J.E. Cheon, I.O. Kim, K.M. Yeon, and H.J. Lee Pulmonary tuberculosis in infants: radiographic and CT findings AJR 187 2006 1024 1033
22. S. Katakura, T. Imagawa, S. Ito, T. Miyamae, T. Mitsuda, and M. Ibe et al. Computed tomography with normal chest radiography in childhood tuberculosis Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 73 1999 130 137 (in Japanese)
23. J.A. Singh, D.E. Furst, A. Bharat, J.R. Curtis, A.F. Kavanaugh, and J.M. Kremer et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res 64 2012 625 639